Australia’s regulator approves Eli Lilly’s GLP‑1 weight‑loss pill Foundayo

The Therapeutic Goods Administration cleared Lilly’s oral GLP‑1 drug, Foundayo (orforglipron), for use in Australia. The company said the pill will be available within days on private prescription, though it is not yet listed on the Pharmaceutical Benefits Scheme. Clinical trials involved more than 10,000 patients across 15 countries.

The approval introduces a new revenue stream for Lilly in the Australian market and gives physicians a daily oral alternative to injectable GLP‑1 therapies. Because the drug is not on the PBS, sales will depend on private‑pay prescriptions.

  • 1The Therapeutic Goods Administration approved Foundayo for Australian use.
  • 2Foundayo is expected to be available in just days after the TGA ruling.
  • 3Clinical trials involved more than 10,000 patients in 15 countries.
  • 4The drug is now available via private prescription but is not yet on the Pharmaceutical Benefits Scheme.
  • 5Around 13 million Australian adults are affected by overweight or obesity, according to the National Association of Clinical Obesity Services.

Sources